Document is current
Any future updates will be listed below
-
Authors
Wenker, Sylvia T. M.
Franssen, Gerben M.
Molkenboer-Kuenen, Janneke D. M.
Konijnenberg, Mark W.
Lobeek, Daphne
Tamborino, Giulia
Peters, Hans
van Lith, Sanne A. M.
Heskamp, Sandra https://orcid.org/0000-0001-7250-0846
Bussink, Johan
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (12567)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150172010054)
- License Information
-
More Information
Article History
Received: 15 June 2026
Revised: 31 August 2026
Accepted: 3 September 2026
First Online: 17 September 2026
Declarations
Conflict of Interest: Sandra Heskamp is co-founder, shareholder and scientific advisor for Aurelius Therapeutics B.V. Sandra Heskamp is an inventor on the patent ‘PSMA-targeting ligands for multimodal applications’ and on a patent involving the combination of [ 177 Lu]Lu-DOTA-hG250 with immune checkpoint inhibitor therapy. The other authors declare that they have no competing interests.
